The EU institutions have reached a provisional political agreement on the revised General Safety Regulation. As of 2022 new safety technologies will become mandatory in European vehicles to protect passengers, pedestrians and cyclists.
New technologies on the market can help reduce the number of fatalities and injuries on our roads, 90% of which are due to human error. In May 2018, the Commission proposed to make certain vehicle safety measures mandatory, including systems that reduce the dangerous blind spots on trucks and buses and technology that warns the driver in case of drowsiness or distraction. Advanced safety features will reduce the number of accidents, pave the way towards increasingly connected and automated mobility, and boost the global innovation and competitiveness edge of the European car industry.
Commissioner Elżbieta Bieńkowska, responsible for Internal Market, Industry, Entrepreneurship and SMEs, said: “Every year, 25,000 people lose their lives on our roads. The vast majority of these accidents are caused by human error. We can and must act to change this. With the new advanced safety features that will become mandatory, we can have the same kind of impact as when the safety belts were first introduced. Many of the new features already exist, in particular in high–end vehicles. Now we raise the safety level across the board, and pave the way for connected and automated mobility of the future.”
The new mandatory safety features include (see full list here):
- For cars, vans, trucks and buses: warning of driver drowsiness and distraction (e.g. smartphone use while driving), intelligent speed assistance, reversing safety with camera or sensors, and data recorder in case of an accident (‘black box’).
- For cars and vans: lane-keeping assistance, advanced emergency braking, and crash-test improved safety belts.
- For trucks and buses: specific requirements to improve the direct vision of bus and truck drivers and to remove blind spots, and systems at the front and side of the vehicle to detect and warn of vulnerable road users, especially when making turns.
The Commission expects that the proposed measures will help save over 25,000 lives and avoid at least 140,000 serious injuries by 2038. This will contribute to the EU’s long-term goal of moving close to zero fatalities and serious injuries by 2050 (“Vision Zero”).
In addition to protecting people on European roads, the new advanced safety features will help drivers get gradually used to the new driving assistance. Increasing degrees of automation offer significant potential to compensate for human errors and offer new mobility solutions for the elderly and physically impaired. All this should enhance public trust and acceptance of automated cars, supporting the transition towards autonomous driving.
The political agreement reached by the European Parliament, Council and Commission in so-called trilogue negotiations is now subject to formal approval by the European Parliament and Council.The new safety features will become mandatory from 2022, with the exception of direct vision for trucks and buses and enlarged head impact zone on cars and vans, which will follow later due to the necessary structural design changes.
In recent years, the EU has introduced a range of mandatory measures, which contributed to an estimated reduction of 50,000 fatal traffic casualties per year. These measures include electronic stability control systems on all vehicles, as well as advanced emergency braking systems and lane departure warning systems on trucks and buses.
In 2017, the Commission launched a public consultation to gather stakeholder views on potential improvements to current vehicle safety measures. In May 2018, the Commission then proposed a review of the General Safety Regulation and the Pedestrian Safety Regulation, under the Third “Europe on the Move” set of actions. The revised General Safety Regulation goes hand in hand with an efficient safety management of road infrastructure, where the Commission’s proposal was agreed in February 2019.
The Commission also presented a Communication on Connected and Automated Mobility to make Europe a world leader for autonomous and safe mobility systems. As a first deliverable for connected mobility the Commission had adopted new rules that step up the deployment of Cooperative Intelligent Transport Systems (C-ITS) on Europe’s roads. C-ITS allow vehicles to ‘talk’ to each other, to the road infrastructure, and to other road users – for instance about dangerous situations, road works and the timing of traffic lights, making road transport safer, cleaner and more efficient.
PURA Announces Hemp4mula CBD Confections Rebranding
Puration, Inc. (USOTC: PURA) today announced initiating efforts to rebrand its recently acquired Hemp4mula CBD confections business.
PURA launched a campaign earlier this year to acquire CBD infused beverage, edible and topical operations. The acquisition campaign is backed by a $5 million investment to fund the acquisitions. The $5 million investment is structured as a debt facility whereby funds can be drawn as needed to fund acquisitions. The drawn funds are secured by the acquired asset and the debt can be repaid in stock at $0.10 per share.
PURA acquired the Hemp4mula CBD Confections business from Kali-Extracts (USOTC: KALY). The Hemp4mula CBD Confections line today sells CBD infused gummies and gum. PURA plans to expand the product line and update the brand image. The Hemp4mula gummies and gum are currently available for sale on www.USMJ.com, an eCommerce website from North American Cannabis Holdings, Inc. (USOTC: USMJ).
PURA also recently announced the acquisition of a CBD Infused Pet Products operation. The seller currently provides concierge pet services through an online portal and the CBD Infused Pet Product Line will bear the name of the portal. PURA will have access to the portal and the existing customer base in conjunction with the purchase agreement. The CBD pet products market is anticipated to reach $1.16 billion in the U.S. alone by 2022
PURA is currently working to build a pipeline of more acquisition opportunities.
For more information on Puration, visit http://www.purationinc.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced that all subjects participating in its 755-101-HV Phase 1 clinical trial have completed treatment and clinical evaluation.
Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period. With treatment completed, InMed continues to anticipate reporting final study results in the second half of calendar 2020.
“The end of the treatment phase is an exciting milestone and we now progress into sample analysis and data review,” said Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs. “The interim safety analysis of the blinded data from the first 16 subjects who had completed at least one week of treatment in this trial supported moving forward with activities to launch a second Phase 1 trial.” The Clinical Trial Application (“CTA”) for InMed’s second Phase 1 study with INM-755, Study 755-102-HV, was filed March 23, 2020.
Some aspects of biological sample and data analyses will be delayed by COVID-19 pandemic-related restrictions and will impact the timing of announcing final study results. InMed is continually reviewing timelines, given current work restrictions in the Netherlands where our Phase 1 studies are being conducted. Changes to INM-755 program timelines, including enrollment in the 755-102-HV trial and the subsequent timing of regulatory filings in preparation for an initial EB patient trial, will be communicated as the Company gains additional information.
In addition, InMed President and CEO Eric A. Adams added, “We want to reassure our stakeholders that our clinical studies and subsequent sample analyses are conducted outside of the hospital setting, and, therefore, do not compete for the critical resources and medical staff needed to address this pandemic. We also continue to take all possible and responsible measures to protect our staff and minimize business disruption.”
The Green Organic Dutchman Announces Additional $35 Million Credit Facilities
The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF), a leading producer of premium certified organic cannabis, is pleased to announce that the Company has entered into a $30 million secured revolving credit facility (the “Facility”) with a private lender (the “Lender”) that is secured on accounts receivable and inventory, with a second lien over the Company’s other assets. The Facility has an initial term of one-year, subject to renewal for up to an additional year.
Upon closing of the Facility, TGOD will be able to draw $10 million. The remaining $20 million will become available as TGOD ramps up its operations and additional borrowing base becomes available from inventory and accounts receivable generated from operations. The Company’s existing lender (the “Senior Lender”) has also agreed to advance an incremental $5 million on the Company’s accordion facility, pending the amendment of the existing credit agreement.
In conjunction with the closing of the Facility and the advance on the Company’s accordion facility, the Company will grant, to the Lender and the Senior Lender, respectively, 3,000,000 warrants to purchase common shares and 1,500,000 warrants to purchase common shares (collectively “Warrants”). The Warrants will have an exercise price of $0.39 and expire in three years.
The Facility is subject to the completion of customary closing conditions, including satisfactory documentation, and conditional listing approval of the shares issuable under the Warrants, with expected completion of conditions precedent and closing by April 20, 2020. The underwriter of the Company’s previously announced bought deal public offering of units has consented to the entering into of the Facility and the advance on the accordion facility.
SOURCE The Green Organic Dutchman Holdings Ltd.
Cannabis3 weeks ago
Intec Pharma Reports Fourth Quarter and Year End 2019 Financial Results and Corporate Update
Cannabis3 weeks ago
Allied Corp. Announces Corporate Update
Cannabis3 weeks ago
SparqOne Announces California Distribution of Iconic Cannabis Brands
Cannabis4 weeks ago
Happy Brain Licenses Iconic Kushy Punch Brand
Cannabis3 weeks ago
Hemp, Inc.’s Great American Hempathon Attracting Participants from Around the World
Cannabis3 weeks ago
CBD Skin Care Market All Set to Grow with a CAGR of 24.80% By 2026
Cannabis3 weeks ago
IGNITE Partners with VapeEZ for Dubai Distribution of new IGNITE NIC product line
Cannabis4 weeks ago
Green Cures & Botanical Distribution Hires David Moceri as new Chief Marketing Officer